ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Chronic Total Occlusion Market is expected to grow at 8.1% CAGR to account to US$ 516.1 Mn by 2025 – Integer Holdings Corporation, Baylis Medical Company, C. R. Bard, Boston Scientific Corporation

Chronic Total Occlusion Market is expected to grow at 8.1% CAGR to account to US$ 516.1 Mn by 2025  - Integer Holdings Corporation, Baylis Medical Company, C. R. Bard, Boston Scientific Corporation
The List of Companies

ASAHI INTECC CO., LTD.
SoundBite Medical Solutions
Integer Holdings Corporation
Baylis Medical Company, Inc.
SPECTRANETICS
C. R. Bard, Inc.
Boston Scientific Corporation
Medtronic
Terumo Corporation
Cordis
Abbott
According to a new market research study titled Chronic Total Occlusion Market - The report highlights the trends prevalent in the global chronic total occlusion market and the factors driving the market along with those that act as deterrents to its growth.

Global chronic total occlusion market, based on end user was segmented hospitals, ambulatory care centers and others. In 2017, hospitals segment held the largest share of the market, by end user. CTOs are blockages that have typically been present for above than three months. These blockages are a result of severe build-up of fatty deposits or plaque within the arteries (atherosclerosis) and are one of the complications from coronary artery disease (CAD). Hospitals dominate the end user segment as it is the primary health systems in most of the countries. Hence the number of CTO procedures in hospitals is more than any other healthcare facility. Also, increasing adoption of new technology devices in the hospitals and rising hospital research drives the market growth. Thus, hospitals is expected to dominate the end-user segment during the forecast period.

The chronic total occlusion market is expected to grow as increasing demand for minimally invasive surgical procedures, rising prevalence of artery diseases, technological advancements, and rising geriatric population are expected to fuel the market growth during the forecast period. In addition, increasing medical tourism in emerging nations are likely to have a positive impact on the growth of the global chronic total occlusion market in the coming years.

The major players operating in the chronic total occlusion market are ASAHI INTECC CO., LTD, SoundBite Medical Solutions, Integer Holdings Corporation, Baylis Medical Company, Inc, SPECTRANETICS, C. R. Bard, Inc., Boston Scientific Corporation, Medtronic, Terumo Corporation, Cordis, and Abbott. For instance, in August 2017, Koninklijke Philips N.V. completed the acquisition of The Spectranetics Corporation in order to accelerate its strategic expansion into cardiovascular devices.

Get Sample Copy of Research @ https://www.theinsightpartners.com/sample/TIPMD00002711/

 

Equipment Insights

The global chronic total occlusion market by equipment was led by the guidewires segment. In 2017, the ablation devices segment held a largest market share of 41.9% of the chronic total occlusion market, by equipment. The segment is also expected to dominate the market during the year 2025, since they offer ease in various medical procedures.

 

End User Insights

The chronic total occlusion market by end user was segmented into hospitals, ambulatory care centers and others. The hospitals segment held the largest share of the market, by end user with a share of around 61.9%. The segment is also expected to dominate during the year 2025, due to rapid technological advancements and growing investments in healthcare facilities.

 

Strategic Insights

Acquisitions and approvals were observed as the most adopted strategy in global chronic total occlusion industry. Few of the acquisitions and approvals made by the players in the market are listed below:

2018: In April, 2018, Asahi Intecc Co., Ltd received CTO indication from US FDA for its PTCA guidewires: ASAHI Gaia series, MIRACLEBROS/ASAHI Miracle series, CONFIANZA/Conquest series, FIELDER XT, FIELDER XT-A, FIELDER XT-R, ULTIMATEbros 3 and Microcatheters: ASAHI Corsair, Corsair Pro microcatheters.

2017: In August, 2017, Koninklijke Philips N.V. acquired The Spectranetics Corporation. This acquisition will accelerate Philip’s strategic expansion into therapy devices.

 

Get 10% Free Customization on Purchase @ https://www.theinsightpartners.com/buy/TIPMD00002711/  

 

About US:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Automotive, Electronics and Chemical industries.

Media Contact
Company Name: The Insight Partners
Contact Person: Sam J
Email: Send Email
Phone: +1-646-491-9876
Address:Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: https://www.theinsightpartners.com/reports/chronic-total-occlusion-market



Source: www.abnewswire.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.